About Rhenovia Pharma
Rhenovia Pharma is a company based in Mulhouse (France) founded in 2007. Rhenovia Pharma has raised $728 thousand across 2 funding rounds from investors including European Union. Rhenovia Pharma offers products and services including Blog Articles and Contact Form. Rhenovia Pharma operates in a competitive market with competitors including GSK, Avidity Biosciences, Sutro Biopharma, Antheia and Vividion Therapeutics, among others.
- Headquarter Mulhouse, France
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$728 K (USD)
in 2 rounds
-
Latest Funding Round
$728 K (USD), Series B
Feb 12, 2014
- Investors
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Rhenovia Pharma
Rhenovia Pharma offers a comprehensive portfolio of products and services, including Blog Articles and Contact Form.
Educational posts on health and beauty for public awareness
Tool for user inquiries and feedback submissions
Funding Insights of Rhenovia Pharma
Rhenovia Pharma has successfully raised a total of $728K across 2 strategic funding rounds. The most recent funding activity was a Series B round of $728 thousand completed in February 2014. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Rhenovia Pharma
Rhenovia Pharma has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include European Union.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability
|
Locked | Locked | Locked |
Investor details for Rhenovia Pharma
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Rhenovia Pharma
Investment portfolio details for Rhenovia Pharma
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Rhenovia Pharma
Detailed financials for Rhenovia Pharma
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Rhenovia Pharma Comparisons
Peer comparison for Rhenovia Pharma
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Rhenovia Pharma
Rhenovia Pharma operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as GSK, Avidity Biosciences, Sutro Biopharma, Antheia and Vividion Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of pharmaceuticals and vaccines for various therapeutic areas
|
|
| Locked | Locked | Locked |
Antibody-siRNA complexes are developed for cancer treatment.
|
|
| Locked | Locked | Locked |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis.
|
|
| Locked | Locked | Locked |
Yeast cells are genetically engineered to produce medicinal products.
|
|
| Locked | Locked | Locked |
Developing novel drugs based on a proteome-wide ligand and target discovery platform
|
|
| Locked | Locked | Locked |
CRISPR-engineered cell and gene therapies are developed for research applications.
|
Detailed competitors of Rhenovia Pharma
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Rhenovia Pharma
Complete news archive for Rhenovia Pharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Rhenovia Pharma
Rhenovia Pharma was founded in 2007 and raised its 1st funding round 6 years after it was founded.
Rhenovia Pharma is headquartered in Mulhouse, France. It is registered at Mulhouse, Grand Est, France.
Rhenovia Pharma is a funded company, having raised a total of $728K across 2 funding rounds to date.
Founded in 2007 and based in Mulhouse, France, Rhenovia Pharma operates in the biopharmaceutical sector with a focus on biosimulation for nervous system drug discovery and development. Technologies are applied to model synaptic transmission, including excitatory and inhibitory processes, for diseases like Alzheimers, depression, schizophrenia, epilepsy, stroke, Parkinsons, and rare conditions such as Huntingtons. The RHENOMS platform simulates cognitive deficits and pathologies involving GLUGABA homeostasis, Ca2 regulation, and acetylcholine deregulation.
Rhenovia Pharma's top competitors include Sutro Biopharma, Synthego and Avidity Biosciences.
Rhenovia Pharma offers Blog Articles and Contact Form.
Rhenovia Pharma has 1 investor. Key investors include European Union.